-
Increased risk of arterial thromboembolism, including myocardial infarction and cerebrovascular events for patients treated with thalidomide.
-
Updated dosing for paediatric paracetamol liquids has been developed to ensure children receive the optimum dose for their age.
-
A reminder to healthcare professionals to fill out Yellow Card reports.
-
Risk of venous thromboembolism (VTE) for drospirenone-containing combined oral contraceptives (COCs), including Yasmin, is higher than for levonorgestrel-containing COCs.
-
Atypical femoral fractures reported rarely with bisphosphonate therapy, mainly in patients receiving long-term treatment for osteoporosis.
-
Risks of Nicobrevin outweigh any benefits.
-
Healthcare professionals should be aware of this risk when prescribing prasugrel.
-
Reminder to monitor and manage weight, glucose, and lipid levels.
-
Use only when other antibiotics are unsuitable
-
Where possible, use an appropriate alternative therapy for patients at increased risk of thrombosis.
-
Stavudine should only be used when there are no appropriate alternatives, and for the shortest possible time.
-
Further information is available to support safer use
-
Risk of developing progressive multifocal leukoencephalopathy (PML) associated with natalizumab is increased in patients who have had previous immunosuppressant therapy.
-
Prescribers should be vigilant for possible thrombotic adverse reactions.
-
Patients receiving lenalidomide for management of multiple myeloma should be closely monitored for evidence of arterial and venous thromboembolic events.
-
Risk of aseptic peritonitis with Dianeal, Extraneal, and Nutrineal peritoneal dialysis solutions due to possible presence of endotoxin.
-
If eosinophilic pneumonia is suspected, daptomycin should be discontinued immediately and if appropriate the patient treated with corticosteroids.
-
If pioglitazone is used in combination with insulin patients should be observed for signs and symptoms of heart failure, weight gain, and oedema.
-
(Dextro)propoxyphene can have serious effects on the electrical activity of the heart (resulting in prolongation of the P-R and Q-T intervals, and widened QRS complexes), even at normal therapeutic doses.
-
Dental examination and appropriate preventive dentistry should be considered before treatment with bevacizumab or sunitinib.
-
-
Use in pelvic inflammatory disease only when other antibacterials are inappropriate or ineffective.
-
Sitaxentan (Thelin▼) withdrawn due to hepatotoxicity.
-
No evidence of increased risk of febrile convulsions in children.
-
Saquinavir at a reduced dose for the first week of treatment
-
Differences in dose delivery between the pump device and dropper device for memantine.
-
Safety studies of Spiriva Respimat▼
-
Drug interactions involving CYP2D6, genetic variants, and variability in clinical response
-
Insufficient evidence to confirm a link between oral bisphosphonate use and an increased risk of oesophageal cancer.
-
Report of febrile promptly.
-
All healthcare professionals trained in inserting Implanon must make sure they are trained in using Nexplanon before the changeover.
-
Second year safety review
-
Suspension of the marketing authorisations of rosiglitazone (Avandia, Avandamet) recommended across the European Union.
-
Should not be used for cough under 18 years
-
Outline of the safety experience of these medicines in the UK from our proactive safety monitoring strategy.
-
Prescribers should remain vigilant with regards to the similarity of these 2 drug names.
-
Benefits of these medicines used in conjunction with inhaled corticosteroids (ICS) in the control of asthma symptoms in children outweigh any apparent risks.
-
Check pumps after MRI.
-
Risk of psychological and behavioural side effects.
-
Update on managing risk of misuse.
-
Erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis reported in association with isotretinoin - may result in hospitalisation, disability, life-threatening events, or death.
-
Aluminium can be leached from glass after contact with calcium gluconate solution, leading to a risk of exposure to aluminium. Accumulation of aluminium might have adverse effects on bone mineralisation and neurological deve…
-
European Medicines Agency has recommends the use of modafinil should be restricted to treat only sleepiness associated with narcolepsy - should no longer be used for obstructive sleep apnoea or chronic shift work sleep disor…
-
European Medicines Agency says further measures should be put in place to minimise the risk of adverse skin reactions.
-
Patients should be transferred to alternative bronchodilator therapy.
-
Risk of accidental overdose, particularly in infants and neonates.
-
Infusion reactions and hypersensitivity reactions have been reported commonly during treatment with Avastin.
-
Medication errors and inappropriate use of the rivastigmine transdermal patch have been reported, some of which resulted in overdose. Healthcare professionals should be aware of the correct use of rivastigmine, and should ad…
-
Quinine should only be considered when cramps cause regular disruption of sleep.
-
Best practice example of a patient information leaflet.